- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cancer risk in immune-mediated inflammatory diseases (IMID) ; volume:12 ; number:1 ; day:29 ; month:8 ; year:2013 ; pages:1-12 ; date:12.2013
Molecular cancer ; 12, Heft 1 (29.8.2013), 1-12, 12.2013
- Urheber
-
Beyaert, Rudi
Beaugerie, Laurent
Van Assche, Gert
Brochez, Lieve
Renauld, Jean-Christophe
Viguier, Manuelle
Cocquyt, Veronique
Jerusalem, Guy
Machiels, Jean-Pascal
Prenen, Hans
Masson, Pierre
Louis, Edouard
De Keyser, Filip
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-12-98
- URN
-
urn:nbn:de:101:1-2021082220064528710651
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Beyaert, Rudi
- Beaugerie, Laurent
- Van Assche, Gert
- Brochez, Lieve
- Renauld, Jean-Christophe
- Viguier, Manuelle
- Cocquyt, Veronique
- Jerusalem, Guy
- Machiels, Jean-Pascal
- Prenen, Hans
- Masson, Pierre
- Louis, Edouard
- De Keyser, Filip
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune monitoring and treatment in immune-mediated inflammatory diseases
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
Recent advances of exosomes in immune-mediated eye diseases
Immune monitoring and treatment in immune-mediated inflammatory diseases
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
Recent advances of exosomes in immune-mediated eye diseases
Immune monitoring and treatment in immune-mediated inflammatory diseases
Urine metabolome profiling of immune-mediated inflammatory diseases
IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
CXCL13: a common target for immune-mediated inflammatory diseases
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease